ExoDisc™ performance data comes from independent researchers and leading journals, not internal testing alone.
EV Recovery Comparison
Head-to-head comparison of EV recovery rates across isolation methods, based on published data.
Source: Woo et al., ACS Nano 2017; Cho et al., Theranostics 2019
~95%
EV recovery
From biosamples, validated by independent researchers using NTA and protein quantification.
ACS Nano, 2017
<5%
inter-assay CV
Reproducibility across independent labs and operators, surpassing all conventional methods.
Theranostics, 2019
~20x
higher yield
Compared to ultracentrifugation, the previous gold standard for EV isolation.
Published data
Publications
Woo HK, Sunkara V, Park J, et al.
Original ExoDisc paper demonstrating centrifugal microfluidic EV isolation from biosamples with ~95% recovery. Established the technical foundation for the platform.
View Paper (opens in new tab)Sunkara V, Kim CJ, Park J, et al.
Validated ExoDisc performance for clinical sample types. Demonstrated inter-disc CV <5% and suitability for downstream biomarker analysis.
View Paper (opens in new tab)Sunkara V, Park J, Han J, et al.
Comparative study of EV isolation methods. Contextualized ExoDisc's performance advantages over precipitation-based approaches.
View Paper (opens in new tab)Lee C, Kumar S, Park J, Choi Y, Clarissa EM, Cho YK.
Demonstrates ExoDisc as an EV drug loading platform. Enables EV-based therapeutic development using standardized isolation.
View Paper (opens in new tab)Kim CJ, Kuczler MD, Dong L, et al.
Step-by-step validated protocol for EV uptake studies using ExoDisc-isolated vesicles. Used in academic and translational research settings.
View Paper (opens in new tab)Leung J, Pollalis D, Nair GKG, et al.
Demonstrates ExoDisc use in ophthalmology translational research. Validates compatibility with clinical investigational workflows for stem cell-derived EV therapeutics.
View Paper (opens in new tab)Technology
ExoDisc uses lab-on-a-disc technology. Centrifugal force drives sample fluid through size-selective microfluidic channels; no pumps, valves, or external pressure required.
As the disc spins, sequential filtration stages separate EVs (30-200 nm) from larger particles, cell debris, and free proteins. The single-use cartridge eliminates cross-contamination risk.
The result: highly purified EVs in a standardized buffer, delivered reproducibly in under 30 minutes from any standard biological fluid.
Our science team is ready to discuss protocols, validation data, and integration support.
